Evidence map›Paper›PMID 40575415›Full record

ArticleNeuro-oncology advances

PNOC009: Convection-enhanced delivery of liposomal irinotecan in patients with newly diagnosed diffuse intrinsic pontine glioma.

Sabine Mueller, Cassie Kline, Alex Y Lu, Raoull Hoogendijk, Eva Wembacher-Schroeder, Anuradha Banerjee, Alyssa T Reddy, Shannon Raber, Carly Hoffman, Schuyler Stoller and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sabine MuellerDepartment of Pediatrics, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-3452-5150
Cassie KlineDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-7765-7690
Alex Y LuDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Raoull HoogendijkDepartment of Neurology, Brain Tumor Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Netherlands.ORCID https://orcid.org/0000-0002-8033-2093
Eva Wembacher-SchroederBrainlab AG, Munich, Germany.
Anuradha BanerjeeCenter for Cancer and Blood Disorders, University of California, San Francisco, San Francisco, CA, USA.
Alyssa T ReddyDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.
Shannon RaberDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.
Carly HoffmanDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0831-4285
Schuyler StollerDepartment of Neurology, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-1931-7521
Michael PradosDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-9630-2075
Annette MolinaroDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Nalin GuptaDepartment of Pediatrics, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-9539-7052

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Median survival in patients with diffuse intrinsic pontine glioma (DIPG) varies between 11 months for children and 20 months for adults. There is no standard of care treatment other than radiation therapy. This study aimed to determine the safety, tolerability, and distribution of nanoliposomal irinotecan (nal-IRI) delivered via CED in patients with DIPG. Methods: Newly diagnosed DIPG patients > 2 years were eligible for enrollment. Dose level (DL) 1 and 2 were completed (DL1 = 2 mL of nal-IRI [20 mg/mL] DL2 = 3 mL of nal-IRI [20 mg/mL]). Nal-IRI was co-infused with gadoteridol via CED to achieve maximal tumor coverage. The distribution of infusate mixture was monitored with real-time magnetic resonance imaging (MRI). The study employed an accelerated dose escalation approach and transitioned to a conventional 3 + 3 design based on predefined rules. The study was terminated prematurely due to the discontinuation of drug supply by industry partner. Results: Six patients (median age 10 years, range 5-40) underwent a total of 13 treatments (median 2, range 1-5/patient). Four grade 3 adverse events, (muscle weakness Conclusions: Repeated CED of nal-IRI in patients with DIPG demonstrated an acceptable risk profile with reasonable tumor coverage. Additional investigations utilizing this strategy should be evaluated in a larger patient cohort to determine efficacy.

Indexed as

convection-enhanced deliveryDIPGnano liposomal irinotecan

Identifiers

PMID40575415
PMCPMC12202035

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.